Objective:
To review the benefits and adverse effects of GLP-1 receptor agonists (GLP-1RAs) in glaucoma and other ocular diseases, highlighting their increasing prescription rates and potential significance in ocular health.
Key Findings:
- GLP-1RAs may lower intraocular pressure and have neuroprotective effects on retinal ganglion cells.
- Mixed results exist regarding the risk of diabetic retinopathy (DR) progression with GLP-1RA use, necessitating careful interpretation of the data.
Interpretation:
While GLP-1RAs show promise in ocular disease management, particularly in reducing risks associated with glaucoma and AMD, further prospective studies are essential to confirm these benefits and clarify conflicting evidence regarding DR.
Limitations:
- Confounding health factors complicate the assessment of ocular adverse events, particularly in retrospective studies.
- Retrospective studies may not accurately capture the incidence of conditions like NAION, leading to potential underreporting.
Conclusion:
GLP-1RAs may offer protective benefits in ocular diseases, but ongoing research is crucial to establish their role in ophthalmology and clarify risks associated with their use.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
